Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

3.200 +0.570 (+21.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,000,901
Open 2.650
Bid (Size) 3.200 (1)
Ask (Size) 3.220 (40)
Prev. Close 2.630
Today's Range 2.640 - 3.210
52wk Range 0.2700 - 3.210
Shares Outstanding 19,169,216
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Monday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire

Performance

YTD
+611.1%
+611.1%
1 Month
+75.8%
+75.8%
3 Month
+474.4%
+474.4%
6 Month
+728.8%
+728.8%
1 Year
+283.2%
+283.2%

More News

Read More
ImmunoPrecise (IPA) Q4 2025 Earnings Transcript
Via The Motley Fool
Earnings Scheduled For July 29, 2025
Via Benzinga
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tech Momentum Surges as IPA, HIT, SNYR, PNPN.V, KAPA and Others Drive Investor Awareness – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Earnings
These stocks are moving in today's session
Via Chartmill
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
On Friday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
AI & Tech Breakout: PRSO, IPA, NEHC, SOAR Lead Today’s Innovation Surge – More Movers Inside
Via AB Newswire
Topics Artificial Intelligence
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
From ImmunoPrecise Antibodies Ltd.
Via Business Wire

Frequently Asked Questions

Is ImmunoPrecise Antibodies Ltd. - Common Stock publicly traded?
Yes, ImmunoPrecise Antibodies Ltd. - Common Stock is publicly traded.
What exchange does ImmunoPrecise Antibodies Ltd. - Common Stock trade on?
ImmunoPrecise Antibodies Ltd. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunoPrecise Antibodies Ltd. - Common Stock?
The ticker symbol for ImmunoPrecise Antibodies Ltd. - Common Stock is IPA on the Nasdaq Stock Market
What is the current price of ImmunoPrecise Antibodies Ltd. - Common Stock?
The current price of ImmunoPrecise Antibodies Ltd. - Common Stock is 3.200
When was ImmunoPrecise Antibodies Ltd. - Common Stock last traded?
The last trade of ImmunoPrecise Antibodies Ltd. - Common Stock was at 08/22/25 04:00 PM ET
What is the market capitalization of ImmunoPrecise Antibodies Ltd. - Common Stock?
The market capitalization of ImmunoPrecise Antibodies Ltd. - Common Stock is 61.34M
How many shares of ImmunoPrecise Antibodies Ltd. - Common Stock are outstanding?
ImmunoPrecise Antibodies Ltd. - Common Stock has 61M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.